We  ||| S:0 E:3 ||| PRP
should  ||| S:3 E:10 ||| MD
be  ||| S:10 E:13 ||| VB
measuring  ||| S:13 E:23 ||| VBG
genomic  ||| S:23 E:31 ||| JJ
bacterial  ||| S:31 E:41 ||| JJ
load  ||| S:41 E:46 ||| NN
and  ||| S:46 E:50 ||| CC
virulence  ||| S:50 E:60 ||| JJ
factors  ||| S:60 E:68 ||| NNS
To  ||| S:68 E:71 ||| TO
describe  ||| S:71 E:80 ||| VB
relevant  ||| S:80 E:89 ||| JJ
pathogen-related  ||| S:89 E:106 ||| JJ
characteristics  ||| S:106 E:122 ||| NNS
and  ||| S:122 E:126 ||| CC
their  ||| S:126 E:132 ||| PRP$
impact  ||| S:132 E:139 ||| NN
on  ||| S:139 E:142 ||| IN
sepsis  ||| S:142 E:149 ||| JJ
pathogenesis  ||| S:149 E:162 ||| NN
and  ||| S:162 E:166 ||| CC
prognosis ||| S:166 E:175 ||| NN
.  ||| S:175 E:177 ||| .
Current  ||| S:177 E:185 ||| JJ
literature  ||| S:185 E:196 ||| NN
regarding  ||| S:196 E:206 ||| VBG
genomic  ||| S:206 E:214 ||| JJ
bacterial  ||| S:214 E:224 ||| JJ
load  ||| S:224 E:229 ||| NN
and  ||| S:229 E:233 ||| CC
virulence  ||| S:233 E:243 ||| JJ
factors ||| S:243 E:250 ||| NNS
,  ||| S:250 E:252 ||| ,
with  ||| S:252 E:257 ||| IN
an  ||| S:257 E:260 ||| DT
emphasis  ||| S:260 E:269 ||| NN
on  ||| S:269 E:272 ||| IN
the  ||| S:272 E:276 ||| DT
impact  ||| S:276 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
these  ||| S:286 E:292 ||| DT
factors  ||| S:292 E:300 ||| NNS
on  ||| S:300 E:303 ||| IN
pathophysiology  ||| S:303 E:319 ||| NN
and  ||| S:319 E:323 ||| CC
prognosis  ||| S:323 E:333 ||| NN
of  ||| S:333 E:336 ||| IN
sepsis ||| S:336 E:342 ||| NN
.  ||| S:342 E:344 ||| .
The  ||| S:344 E:348 ||| DT
current  ||| S:348 E:356 ||| JJ
paradigm  ||| S:356 E:365 ||| NN
on  ||| S:365 E:368 ||| IN
sepsis  ||| S:368 E:375 ||| JJ
pathophysiology  ||| S:375 E:391 ||| NN
and  ||| S:391 E:395 ||| CC
management  ||| S:395 E:406 ||| NN
overlooks  ||| S:406 E:416 ||| NN
aspects  ||| S:416 E:424 ||| NNS
concerning  ||| S:424 E:435 ||| VBG
the  ||| S:435 E:439 ||| DT
nature  ||| S:439 E:446 ||| NN
and  ||| S:446 E:450 ||| CC
characteristics  ||| S:450 E:466 ||| NNS
of  ||| S:466 E:469 ||| IN
the  ||| S:469 E:473 ||| DT
infecting  ||| S:473 E:483 ||| JJ
pathogen ||| S:483 E:491 ||| NN
.  ||| S:491 E:493 ||| .
Our  ||| S:493 E:497 ||| PRP$
findings  ||| S:497 E:506 ||| NNS
suggest  ||| S:506 E:514 ||| VBP
that  ||| S:514 E:519 ||| DT
evaluation  ||| S:519 E:530 ||| NN
of  ||| S:530 E:533 ||| IN
genomic  ||| S:533 E:541 ||| JJ
bacterial  ||| S:541 E:551 ||| JJ
load  ||| S:551 E:556 ||| NN
might  ||| S:556 E:562 ||| MD
be  ||| S:562 E:565 ||| VB
useful  ||| S:565 E:572 ||| JJ
to  ||| S:572 E:575 ||| TO
assess  ||| S:575 E:582 ||| VB
severity  ||| S:582 E:591 ||| NN
and  ||| S:591 E:595 ||| CC
predict  ||| S:595 E:603 ||| VBP
prognosis  ||| S:603 E:613 ||| VBN
in  ||| S:613 E:616 ||| IN
septic  ||| S:616 E:623 ||| JJ
patients ||| S:623 E:631 ||| NNS
;  ||| S:631 E:633 ||| :
its  ||| S:633 E:637 ||| PRP$
use  ||| S:637 E:641 ||| NN
during  ||| S:641 E:648 ||| IN
treatment  ||| S:648 E:658 ||| NN
for  ||| S:658 E:662 ||| IN
monitoring  ||| S:662 E:673 ||| VBG
clinical  ||| S:673 E:682 ||| JJ
response  ||| S:682 E:691 ||| NN
is  ||| S:691 E:694 ||| VBZ
another  ||| S:694 E:702 ||| DT
interesting  ||| S:702 E:714 ||| JJ
potential  ||| S:714 E:724 ||| JJ
application ||| S:724 E:735 ||| NN
.  ||| S:735 E:737 ||| .
Virulence  ||| S:737 E:747 ||| JJ
factors  ||| S:747 E:755 ||| NNS
identification  ||| S:755 E:770 ||| NN
might  ||| S:770 E:776 ||| MD
help  ||| S:776 E:781 ||| VB
to  ||| S:781 E:784 ||| TO
develop  ||| S:784 E:792 ||| VB
pathogen-specific  ||| S:792 E:810 ||| JJ
therapeutic  ||| S:810 E:822 ||| JJ
strategies  ||| S:822 E:833 ||| NNS
for  ||| S:833 E:837 ||| IN
higher-risk  ||| S:837 E:849 ||| JJ
septic  ||| S:849 E:856 ||| JJ
patients ||| S:856 E:864 ||| NNS
.  ||| S:864 E:866 ||| .
The  ||| S:866 E:870 ||| DT
recognition  ||| S:870 E:882 ||| NN
of  ||| S:882 E:885 ||| IN
the  ||| S:885 E:889 ||| DT
importance  ||| S:889 E:900 ||| NN
of  ||| S:900 E:903 ||| IN
quantifying  ||| S:903 E:915 ||| VBG
the  ||| S:915 E:919 ||| DT
pathogen  ||| S:919 E:928 ||| NN
has  ||| S:928 E:932 ||| VBZ
major  ||| S:932 E:938 ||| JJ
clinical  ||| S:938 E:947 ||| JJ
implications  ||| S:947 E:960 ||| NNS
and  ||| S:960 E:964 ||| CC
will  ||| S:964 E:969 ||| MD
open  ||| S:969 E:974 ||| VB
up  ||| S:974 E:977 ||| RP
a  ||| S:977 E:979 ||| DT
new  ||| S:979 E:983 ||| JJ
field  ||| S:983 E:989 ||| NN
of  ||| S:989 E:992 ||| IN
exploration  ||| S:992 E:1004 ||| NN
of  ||| S:1004 E:1007 ||| IN
therapies  ||| S:1007 E:1017 ||| NNS
targeted  ||| S:1017 E:1026 ||| VBN
at  ||| S:1026 E:1029 ||| IN
anticipating  ||| S:1029 E:1042 ||| VBG
development  ||| S:1042 E:1054 ||| NN
and  ||| S:1054 E:1058 ||| CC
appropriate  ||| S:1058 E:1070 ||| JJ
treatment  ||| S:1070 E:1080 ||| NN
in  ||| S:1080 E:1083 ||| IN
severe  ||| S:1083 E:1090 ||| JJ
sepsis ||| S:1090 E:1096 ||| NN
.  ||| S:1096 E:1098 ||| .
The  ||| S:1098 E:1102 ||| DT
improved  ||| S:1102 E:1111 ||| JJ
detection  ||| S:1111 E:1121 ||| NN
and  ||| S:1121 E:1125 ||| CC
understanding  ||| S:1125 E:1139 ||| NN
of  ||| S:1139 E:1142 ||| IN
bacterial  ||| S:1142 E:1152 ||| JJ
virulence  ||| S:1152 E:1162 ||| NN
factors  ||| S:1162 E:1170 ||| NNS
may  ||| S:1170 E:1174 ||| MD
lead  ||| S:1174 E:1179 ||| VB
to  ||| S:1179 E:1182 ||| TO
specific  ||| S:1182 E:1191 ||| JJ
therapies ||| S:1191 E:1200 ||| NNS
.  ||| S:1200 E:1202 ||| .
